Bulletin
Investor Alert

INmune Bio Inc.

NAS: INMB

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
INmune Bio Inc.

After Hours

 --Quotes are delayed by 20 min

May 27, 2022, 7:46 p.m.

INMB
/zigman2/quotes/206182062/composite

$

6.75

Change

-0.05 -0.74%

Volume

Volume 10

Quotes are delayed by 20 min

/zigman2/quotes/206182062/composite

Previous close

$ 6.33

$ 6.80

Change

+0.47 +7.42%

Day low

Day high

$6.33

$7.00

Open

52 week low

52 week high

$4.63

$30.37

Open

Company Description

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was...

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Valuation

Price to Sales Ratio

909.01

Price to Book Ratio

2.27

Enterprise Value to EBITDA

-1.85

Enterprise Value to Sales

158.89

Efficiency

Total Asset Turnover

0.00

Liquidity

Current Ratio

18.95

Quick Ratio

18.95

Cash Ratio

17.16

Profitability

Operating Margin

-16,106.63

Pretax Margin

-16,762.43

Net Margin

-16,762.43

Return on Assets

-43.16

Return on Equity

-51.00

Return on Total Capital

-43.39

Capital Structure

Total Debt to Total Assets

15.24

Officers and Executives

Name Age Officer Since Title
Dr. Raymond J. Tesi 64 2015 Chairman, President, Chief Executive Officer & CMO
Mr. David J. Moss 49 2015 Chief Financial Officer, Secretary & Treasurer
Dr. Mark Lowdell 57 2015 Chief Scientific & Manufacturing Officer
Mr. Joshua S. Schoonover - - Associate General Counsel
Dr. Edgardo Baracchini 60 2019 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/22/2022 Raymond J. Tesi
President and CEO; Director 		23,724   Award at $8.43 per share. 199,993
03/22/2022 Mark Lowdell
Chief Scientific Officer 		23,590   Award at $8.43 per share. 198,863
03/22/2022 David J. Moss
CFO, Treasurer & Secretary 		17,793   Award at $8.43 per share. 149,994
03/22/2022 J. Kelly Ganjei
Director 		17,793   Award at $8.43 per share. 149,994
11/17/2021 Scott Juda
Director 		2,500   Acquisition at $13.55 per share. 33,875
11/03/2021 Raymond J. Tesi
President and CEO; Director 		3,626   Disposition at $20 per share. 72,520
11/03/2021 Mark Lowdell
Chief Scientific Officer 		701   Disposition at $20 per share. 14,020
11/03/2021 David J. Moss
CFO, Treasurer & Secretary 		1,025   Disposition at $20 per share. 20,500
10/27/2021 Raymond J. Tesi
President and CEO; Director 		6,517   Disposition at $20 per share. 130,340
10/27/2021 Mark Lowdell
Chief Scientific Officer 		2,357   Disposition at $20 per share. 47,140
10/27/2021 David J. Moss
CFO, Treasurer & Secretary 		2,079   Disposition at $20 per share. 41,580
10/25/2021 David J. Moss
CFO, Treasurer & Secretary 		13   Disposition at $20 per share. 260
10/22/2021 Raymond J. Tesi
President and CEO; Director 		23,616   Disposition at $20 per share. 472,320
10/22/2021 Mark Lowdell
Chief Scientific Officer 		400   Disposition at $20 per share. 8,000
10/22/2021 David J. Moss
CFO, Treasurer & Secretary 		1,142   Disposition at $20 per share. 22,840
09/03/2021 Xencor, Inc.
108,000   Derivative/Non-derivative trans. at $7.8 per share. 842,400
08/25/2021 Raymond J. Tesi
President and CEO; Director 		30,000   Derivative/Non-derivative trans. at $3.91 per share. 117,300
07/16/2021 David J. Moss
CFO, Treasurer & Secretary 		25,000   Derivative/Non-derivative trans. at $3.91 per share. 97,750
07/13/2021 Timothy J. Schroeder
Director 		14,480   Disposition at $27.63 per share. 400,082
/news/latest/company/us/inmb

MarketWatch News on INMB

  2. INmune Bio downgraded to neutral from buy at B. Riley

    7:51 a.m. May 24, 2022

    - Tomi Kilgore

  3. INmune Bio stock price target cut to $7 from $14 at B. Riley

    7:52 a.m. May 24, 2022

    - Tomi Kilgore

  4. Robinhood investors are propping up this stock market, says JPMorgan

    9:33 a.m. Sept. 2, 2021

    - Barbara Kollmeyer

  5. Analyst Raises Price Targets on 3 Smaller Alzheimer's Stocks

    11:50 a.m. July 7, 2021

    - Barron's Online

  6. INmune Bio stock price target raised to $42 from $32 at Maxim Group

    8:31 a.m. July 7, 2021

    - Tomi Kilgore

  7. INmune Bio started at buy with $29 stock price target at B. Riley

    7:23 a.m. April 21, 2021

    - Tomi Kilgore

  8. INmune Bio stock price target raised to $32 from $16 at Maxim Group

    8:39 a.m. Jan. 22, 2021

    - Tomi Kilgore

  9. INmune Bios started at buy with $13 stock price target at Maxim Group

    7:38 a.m. March 19, 2019

    - Tomi Kilgore

/news/nonmarketwatch/company/us/inmb

Other News on INMB

  2. INmune Bio: Possibly The Once In A Lifetime Dip

    11:28 a.m. May 25, 2022

    - Seeking Alpha

  4. PLG, ZTEK and BBAI among mid-day movers

    1:06 p.m. May 24, 2022

    - Seeking Alpha

  10. INmune Bio, Inc. (INMB) Q1 2022 Earnings Call Transcript

    1:30 p.m. May 6, 2022

    - Motley Fool

  11. Notable earnings after Thursday's close

    5:35 p.m. May 4, 2022

    - Seeking Alpha

  12. Hypotheses Underlying Alzheimer's Drug Development

    1:06 p.m. April 26, 2022

    - Seeking Alpha

  16. KNDI, LILM and ADN among mid- day movers

    12:38 p.m. March 24, 2022

    - Seeking Alpha

  17. INmune Bio, Inc. (INMB) Q4 2021 Earnings Call Transcript

    5:30 a.m. March 4, 2022

    - Motley Fool

  19. 10-K: INMUNE BIO, INC.

    5:05 p.m. March 3, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  20. Anavex Life Sciences: My Thoughts On Their AD Therapy

    9:30 a.m. Feb. 4, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

INmune Bio, Inc.

225 NE Mizner Boulevard

Suite 640

Boca Raton, Florida 33432

Phone

1 8589643720

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$181,000

Net Income

$-30.34M

Employees

10.00

Annual Report for INMB

/news/pressrelease/company/us/inmb

Press Releases on INMB

  21. Loading more headlines...
Link to MarketWatch's Slice.